p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines

Modern Pathology

Volumn 9, Issue 1, 1996, Pages 26-31

  Hirama, Toshiyasu ^a   Miller, Carl W ^b   Wilczynski, Sharon P ^b   Koeffler, H Phillip ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

Cervical cancer; Cyclin dependent kinase inhibitor; Deletion; Mutation

Indexed keywords

CYCLINE; ENDOGENOUS COMPOUND; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; UTERINE CERVIX CARCINOMA;

BLOTTING, SOUTHERN; CARCINOMA; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN KINASE INHIBITORS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0030063169     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Ocadiz R, Sauceda R, Cruz M, Graef AM, Gariglio P: High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix. Cancer Res 47:4173, 1987
2. Riou GF, Barrois M, Dutronquay V, Orth G: Presence of papillomavirus DNA sequences, amplification of c-myc and c-H-ras oncogenes, and enhanced expression of c-myc in carcinoma of the uterine cervix. In Papillomaviruses: Molecular and Clinical Aspects, edited by Howly PM, Broker TR, p 47. New York, Alan R. Liss Inc., 1985
3. zur Hauzen H: Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 49:4677, 1989
4. Atkin NB, Baker MC: Nonrandom chromosome changes in carcinoma of the cervix uteri. II. Ten tumors in the triploid-tetraploid range. Cancer Genet Cytogenet 13: 189, 1984
5. Atkin NB, Baker MC: Nonrandom chromosome changes in carcinoma of the cervix uteri. Acta Cytol 26:568, 1982
6. Atkin NB, Baker MC: Nonrandom chromosome changes in carcinoma of the cervix uteri. I. Nine near diploid tumors. Cancer Genet Cytogenet 7:209, 1982
7. Hampton GM, Penny LA, Baergen RN, Larson A, Brewer C, Liao S, Busby-Earle RMC, Williams AWR, Steel CM, Bird CC, Stanbridge EJ, Evans GA: Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci U S A 91:6953, 1994
8. Srivatsan ES, Misra BC, Venugopalan M, Wilczynski SP: Loss of heterozygosity for alleles on chromosome 11 in cervical carcinoma. Am J Hum Genet 49:868, 1991
9. Yokota J, Tsukada Y, Nakazima T, Gotoh M, Shimosato Y, Mori N, Tsunokawa Y, Sugimura T, Terada M: Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix. Cancer Res 49: 3598, 1989
10. Mitra AB, Murty VWS, Li RG, Pratap M, Luthra UK, Chaganti RSK: Allelotype analysis of cervical cancer. Cancer Res 54:4481, 1994
11. Srivatsan ES, Benedict WF, Stanbridge EJ: Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. Cancer Res 46:6174, 1986
12. Saxon PJ, Srivatsan ES, Stanbridge EJ: Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J 5:3461, 1986
13. Oshimura M, Kugoh H, Koi M, Shimizu M, Yamada H, Satoh H, Barrett JC: Transfer of a normal human chromosome 11 suppresses tumorigenicity of some but not all tumor cell lines. J Cell Biochem 42:135, 1990
14. Kaelbling M, Klinger HP: Suppression of tumorigenicity in human cell hybrids. Cytogenet Cell Genet 41:65, 1986
15. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059, 1993
16. Hunter T, Pines J: Cyclins and cancer. Cell 66:1071, 1991
17. Motokura T, Arnold A: Cyclin D and oncogenesis. Curr Opin Genet Dev 3:5, 1993
18. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 91:709, 1994
19. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669, 1994
20. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704, 1993
21. Harper JW, Adami GR, Wei N, Keromarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805, 1993
22. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI: A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A 91:5292, 1994
23. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day R3, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436, 1994
24. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kanzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993
25. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59, 1994
26. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67, 1994
27. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366:701, 1993
28. Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20k regulatory subunit. Nature 366:707, 1993
29. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257, 1994
30. Hunter T: Braking the cycle. Cell 75:839, 1993
31. kip1, a cyclin-Cdk inhibitor, links transforming growth factor-b and contact inhibition to cell cycle arrest. Genes Dev 8:9, 1994
32. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574, 1994
33. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y: Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202: 1426, 1994
34. Mori T, Miura K, Aoki T, Nishihara T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396, 1994
35. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753, 1994
36. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27, 1994
37. Chen J-Q, Jhanwar SC, Klein WM, Bell DW, Lee W-C, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547, 1994
38. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K, Kurosawa M, Tanaka T, Mitani K, Yazaki Y, Hirai H: Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemia. Blood 84:2431, 1994
39. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldbar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:22, 1994
40. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheehan MD, Clark Jr WH, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 8:15, 1994
41. Spruck CIII, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA: p16 gene in uncultured tumours. Nature 370:183, 1994
42. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415, 1994
43. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, Huebner K: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene CDK4I, in melanoma. Cancer Res 54, 1994
44. ink4) in human breast carcinomas. Cancer Res 54:5262, 1994
45. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM: Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 61:962, 1987
46. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111, 1985
47. Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R, Howley PM: Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 119:361, 1985
48. Scheffner M, Munger K, Byrne JC, Howly PM: The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 88:5523, 1991
49. Monk BJ, Cook N, Ahn C, Vasilev SA, Berman ML, Wilczynski SP: Comparison of the polymerase chain reaction and Southern blot analysis in detecting and typing human papilloma virus deoxyribonucleic acid in tumors of the lower female genital tract. Diagn Mol Pathol, 3:283, 1994
50. Wilczynski SP, Walker J, Bergen S, Liao SY, Pearlman L: Human papillomavirus and cervical carcinomas: Histologic features associated with different viral types. Hum Pathol 19:697, 1988
51. Park DJ, Wilczynski SP, Paquette RL, Miller CW, Koeffler HP: p53 mutations in HPV-negative cervical carcinoma. Oncogene 9:205, 1994
52. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989
53. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874, 1989
54. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A 86:2766, 1989
55. Srivastava S, Tong YA, Devadas K, Zou Z-Q, Chen Y, Pirollo KF, Chang EH: The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines. Carcinogenesis 13:1273, 1992
56. Crook T, Wrede D, Vousden KH: p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6:873, 1991
57. Wrede D, Tidy JA, Crook T, Lane D, Vousden KH: Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carcinogenesis 4:171, 1991
58. Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, Koeffler HP: Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 72: 1272, 1993
59. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howly PM: The E6 oncoprotein encoded by human papillomavirus type 16 and 18 promotes the degradation of p53. Cell 63:1129, 1990
60. Mietz JA, Unger T, Huibregtse JM, Howly PM: The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11:5013, 1992
61. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR: Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci U S A 89:4549, 1992
62. Morris JD, Crook T, Bandara LR, Davies R, LaThangue NB, Vousden KH: Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene 8:893, 1993
63. Werness BA, Levine AJ, Howly PM: Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 248:76, 1990
64. Cao L, Faha B, Dembski M, Tsai LH, Harlow E, Dyson N: Independent binding of the retinoblastoma protein and p 107 to the transcription factor E2F. Nature 355:176, 1992
65. Nevins JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424, 1992
66. cdk2 is a component of the E2F-cyclin A complex. Cell 68:167, 1992
67. Lees E, Faha B, Dulic V, Reed SI, Harlow E: Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev 6:1874, 1992
68. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499, 1993
69. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487, 1993
70. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7:331, 1993
71. Muller H, Lukas J, Schneider A, Warthoe P, Bartek J, Eilers M, Strauss M: Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci U S A 91:2945, 1994
72. Ink4. Cancer Res 54:5816, 1994